Welcome to our dedicated page for American Oncology Network news (Ticker: AONC), a resource for investors and traders seeking the latest updates and insights on American Oncology Network stock.
American Oncology Network Inc (AONC) generates news through practice partnerships, geographic expansion, and clinical research activities. The company's business development announcements reveal its strategy for building a national network of community-based cancer care providers while maintaining physician-led governance.
News coverage for American Oncology Network typically includes partnership announcements with independent oncology and hematology practices joining the network. These affiliation deals expand the company's geographic footprint and add specialized capabilities across different cancer care markets. The network's expansion strategy focuses on preserving local practice identity while integrating operational infrastructure.
Clinical research developments represent another significant news category, as the network presents findings at major oncology conferences and announces participation in multi-site clinical trials. These research activities demonstrate the company's ability to bring investigational therapies to community settings and contribute to cancer treatment evidence.
Regulatory developments, laboratory accreditation milestones, and leadership appointments also generate newsworthy updates. The network's central laboratory services require ongoing certification and compliance oversight, while executive team changes reflect the organization's growth trajectory and strategic priorities.
Track American Oncology Network news to monitor how the physician-led oncology network model evolves in response to healthcare consolidation trends, reimbursement policy changes, and advances in precision medicine that require sophisticated diagnostic and treatment capabilities in community settings.
American Oncology Network (NASDAQ: AONC) reported a 20% revenue increase in Q1 2024, reaching $364.3 million, driven by a 7.1% rise in patient encounters. They added 17 new providers and expanded into Texas and Maryland.
The company faced a net loss of $24.9 million, up from $1.5 million in Q1 2023, due to increased costs, including $13.3 million in equity-based compensation.
Adjusted EBITDA decreased to $2.0 million from $4.1 million year-over-year. Liquidity stood at $132.7 million, aided by a $48.3 million deferral in drug payments.
American Oncology Network (Nasdaq: AONC) announced a change in the release date for its first quarter 2024 financial results, now set for May 20, 2024, before the market opens. A conference call and live webcast will follow on May 21, 2024, at 8:30 a.m. ET. To join the call, dial 1-877-704-4453 (U.S.) or 1-201-389-0920 (international), with passcode 13746298. A replay will be available until May 28, 2024, by dialing 1-844-512-2921 (U.S.) or 1-412-317-6671 (international), using Access ID 13746298. Additionally, AONC plans to file a Form 12b-25 for an automatic extension on its Form 10-Q quarterly report filing.
American Oncology Network (AONC) announced that Dave Gould will step down as Chief Financial Officer, with David Afshar appointed as interim CFO. Afshar brings over 25 years of healthcare finance experience to the role, having worked in both private equity-backed and public company environments. AONC expressed gratitude to Gould for his contributions and emphasized their commitment to providing top-notch cancer care.
American Oncology Network (AONC) will release its first quarter 2024 financial results on May 15, 2024, followed by a conference call and webcast at 8:30 a.m. Eastern Time. Investors can access the call through specific phone numbers and a passcode, with a replay available later. The financial results and webcast will be accessible on the Investor Relations section of the Company's website.
FAQ
What is the current stock price of American Oncology Network (AONC)?
What is the market cap of American Oncology Network (AONC)?
